The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients

Antiviral therapy is a first line of defence against new influenza strains. Current pandemic preparations involve stock- piling oseltamivir, an oral neuraminidase inhibitor (NAI), so rapidly determining the effectiveness of NAIs against new viral strains is vital for deciding how to use the stockpil...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmer, John, Dobrovolny, Hana M., Beauchemin, Catherine A. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220315/
https://www.ncbi.nlm.nih.gov/pubmed/28067324
http://dx.doi.org/10.1038/srep40210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220315/
https://www.ncbi.nlm.nih.gov/pubmed/28067324
http://dx.doi.org/10.1038/srep40210

Ejemplares similares